Resistance to anti-vascular endothelial growth factor (VEGF) molecules causes lack of
response and disease recurrence. Acquired resistance develops as a result of …

Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

Angiogenesis—one of the hallmarks of cancer—has emerged as a valid therapeutic target in
oncology. The VEGF system represents a key mediator of tumor-initiated angiogenesis and …

Vascular endothelial growth factor (VEGF) is the principal regulator of tumor angiogenesis
and is overexpressed in the majority of solid tumors. Therapeutic inhibition of VEGF and its …

Tumor angiogenesis has several undesirable effects on the immune molecules within the
tumor microenvironment. It often severely hampers the ability of immune effectors to control …

Angiogenesis is defined as the formation of new blood vessels from preexisting vessels and
has been characterized as an essential process for tumor cell proliferation and viability. This …

Simple Summary Although VEGF-A is well characterized as the principal player of cancer
angiogenesis, new data on the interplay with other components of the tumor …

Despite setbacks, the clinical development of antiangiogenic agents has accelerated
remarkably over the past 3–4 years. Consequently, there are currently three direct inhibitors …

Antiangiogenesis is a promising antitumor strategy that inhibits tumor vascular formation to
suppress tumor growth. Specifically, targeting VEGF has shown therapeutic benefits in many …

Immune checkpoint blockade (ICB) therapies, such as the ones targeting cytotoxic T
lymphocyte-associated antigen-4 (CTLA-4) or programmed cell death protein 1 (PD-1), have …